AMES, Iowa, April 03, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today it will present at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
NewLink Genetics management will participate in a fireside chat Tuesday, April 10, 2018, entitled “Advances of Immuno-oncology” 8:00 AM – 9:00 AM CET. In addition, management will provide an overview of the Company's business during a live presentation April 10th, 1:20 PM – 1:45PM CET, and will be available for one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
A live webcast of the conference presentation will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events & Presentations.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]


BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
Apple Restores Telegram to App Store After Content Policy Violation
Telegram Restored on Apple App Store After Temporary Removal
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 



